Homology Medicines
1 Patriot Place
Bedford
Massachusetts
01730
United States
Tel: 857-305-1825
Website: http://www.homologymedicines.com/
Email: info@homologymedicines.com
About Homology Medicines
Homology Medicines is based on groundbreaking science that harnesses the naturally occurring process of homologous recombination. This non-nuclease-based approach offers clear advantages in its precision, efficiency and on-target in vivo editing of genetic mutations. Homology obtained an exclusive worldwide license to this technology platform, which is based on the pioneering research of Saswati Chatterjee, Ph.D., Professor of Virology at the Beckman Research Institute at the City of Hope in California, member of the Recombinant DNA Advisory Committee (RAC) to the Office of the Director, National Institutes of Health (NIH) and former charter member of the Therapeutic Approaches to Genetic Diseases Study Section of the NIH. Dr. Chatterjee and her team led the first adeno-associated virus (AAV) vector-mediated gene transfer studies into human hematopoietic stem cells and subsequently identified and isolated a series of naturally-occurring AAVs from human CD34+ cells.
YEAR FOUNDED:
2015
LEADERSHIP:
Founder: Saswati Chatterjee
President and CEO: Arthur Tzianabos, Ph.D.
CSO: Albert Seymour, Ph.D.
113 articles about Homology Medicines
-
Homology Medicines Declares Distribution to Common Stockholders
3/18/2024
Homology Medicines, Inc. announced that it declared a distribution to its common stockholders of record as of the close of business on March 21, 2024 of the right to receive one contingent value right for each outstanding share of Homology common stock held by such stockholder as of such record date.
-
Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
1/3/2024
Homology Medicines, Inc. announced that it received notification from The Nasdaq Stock Market LLC on December 29, 2023 indicating that, for the last thirty consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Global Select Market ).
-
Q32 Bio and Homology Medicines Announce Merger Agreement
11/16/2023
Q32 Bio Inc., a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Homology Medicines, Inc., announced they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.
-
Homology Medicines Reports Third Quarter 2023 Financial Results
11/14/2023
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today third quarter 2023 financial results and highlighted recent updates.
-
Homology Medicines Reports Second Quarter 2023 Financial Results and Recent Highlights
8/14/2023
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today second quarter 2023 financial results and highlighted recent updates.
-
Homology Medicines Announces Plan to Evaluate Strategic Options for the Company and its Genetic Medicines Programs, including HMI-103 Gene Editing Candidate for PKU
7/27/2023
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that it has completed a review of its business, and the Board of Directors has approved a plan to evaluate strategic alternatives to maximize shareholder value.
-
Homology Medicines Announces Encouraging Initial Data from First Dose Level in the pheEDIT Trial Evaluating Gene Editing Candidate HMI-103 in Adults with Classical PKU
7/27/2023
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today encouraging initial clinical data from the first dose cohort in the pheEDIT Phase 1, dose-escalation trial evaluating gene editing candidate HMI-103 in adults with classical phenylketonuria (PKU), the most prevalent and severe form of the disease.
-
Homology Medicines Announces First Data from IND-Enabling Studies with GTx-mAb Candidate HMI-104 for PNH, Which Demonstrated Sustained Expression of Functional C5mAb Levels, at the ASGCT Annual Meeting
5/16/2023
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today six presentations supporting its gene editing, gene therapy and GTx-mAb programs at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting.
-
Homology Medicines Reports First Quarter 2023 Financial Results and Recent Highlights
5/11/2023
Homology Medicines, Inc., a genetic medicines company, announced financial results for the first quarter ended March 31, 2023, and highlighted recent accomplishments.
-
Homology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Studies with GTx-mAb Development Candidate HMI-104 for PNH, at ASGCT Annual Meeting
5/3/2023
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the first presentation of results from IND-enabling studies with HMI-104, the anti-C5 GTx-mAb development candidate for paroxysmal nocturnal hemoglobinuria (PNH).
-
Homology Medicines Announces Presentations on Design of Ongoing Gene Editing and Gene Therapy Trials for PKU and Hunter Syndrome at ACMG Annual Clinical Genetics Meeting
3/15/2023
Homology Medicines, Inc. announced two presentations during the ACMG Annual Clinical Genetics Meeting, which highlight the preclinical data that supported initiation of the Company’s Phase 1 pheEDIT gene editing trial for phenylketonuria and the Phase 1 juMPStart gene therapy trial for Hunter syndrome.
-
Homology Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
3/9/2023
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for the fourth quarter and full year ended December 31, 2022, and highlighted recent accomplishments.
-
Homology Medicines Announces Promotion of Julie Jordan, M.D., to Chief Medical Officer
3/9/2023
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Julie Jordan, M.D., has been promoted to Chief Medical Officer.
-
Homology Medicines to Participate in the 43rd Annual Cowen Healthcare Conference
3/2/2023
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Albert Seymour, Ph.D., President and Chief Executive Officer, will participate in the “Gene Editing Corporate Panel” during the 43rd Annual Cowen Healthcare Conference on Wednesday, March 8, 2023 at 10:30 a.m. ET.
-
Homology Medicines Presents Preclinical Data Supporting Immunosuppression Regimen in Ongoing PKU and Hunter Syndrome Clinical Trials, and Details Optimized MLD Gene Therapy Candidate at the 19th Annual WORLDSymposium™ Meeting
2/22/2023
Homology Medicines, Inc. announced the presentation of preclinical data that supports the targeted, prophylactic immunosuppression regimen in the ongoing pheEDIT gene editing clinical trial in adults with phenylketonuria and juMPStart gene therapy trial in adults with Hunter syndrome.
-
Homology Medicines Provides Update on pheEDIT and juMPStart Clinical Trials and Announces Expected 2023 Milestones, Including Initial Data Read-Outs from Both Programs
1/4/2023
Homology Medicines, Inc., a genetic medicines company, announced enrollment and site status updates from the pheEDIT Phase 1 gene editing trial with HMI-103 for phenylketonuria and the juMPStart Phase 1 gene therapy trial with HMI-203 for Hunter syndrome.
-
Homology Medicines Reports Third Quarter 2022 Financial Results and Recent Highlights
11/10/2022
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for the third quarter ended September 30, 2022, and highlighted recent accomplishments.
-
Homology Medicines Presents on Design of pheEDIT Trial Evaluating One-Time Nuclease-Free Gene Editing Candidate HMI-103 for PKU at American Society of Human Genetics Meeting
10/27/2022
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today a presentation on the design of pheEDIT, a Phase 1, open-label, dose-escalation study evaluating one-time gene editing candidate HMI-103 in adults with phenylketonuria (PKU).
-
Homology Medicines to Participate at Upcoming Conferences - October 06, 2022
10/6/2022
Homology Medicines, Inc., a clinical-stage genetic medicines company, announced participation at the following conferences.
-
Homology Medicines and MiMedx both posted new CEOs. Other C-suite positions, including CFOs and CMOs were also filled this week.